Europe Point Of Care Molecular Diagnostics Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

Europe's point-of-care molecular diagnostics market encompasses rapid molecular testing platforms used across hospitals, clinics, laboratories, and community care settings. These systems detect pathogens, genetic mutations, and disease biomarkers through nucleic acid amplification technologies, delivering results far faster than centralized laboratory methods. The market has benefited from significant technology advances that have miniaturized platforms, improved assay menus, and reduced turnaround times.

• •Focuses on infectious disease testing (influenza, RSV, COVID-19, HIV, tuberculosis) as the dominant application segment
• •Encompasses cartridge-based and microfluidic systems enabling non-specialist operators to run complex molecular assays
• •Supported by growing preference for decentralized care models and hospital-at-home initiatives

The COVID-19 pandemic served as a pivotal catalyst, dramatically expanding awareness and infrastructure for rapid molecular testing across European healthcare systems. Aging populations, rising antimicrobial resistance, and increased surveillance requirements for hospital-acquired infections continue to demand faster diagnostic capabilities. Regulatory frameworks and reimbursement developments in major European markets are increasingly aligning with the clinical value proposition of POC molecular testing.

• •Aging demographics and rising chronic disease burden driving demand for rapid, actionable diagnostics
• •Antimicrobial resistance concerns prompting investment in faster pathogen identification tools
• •Technological miniaturization and workflow simplification expanding accessibility in non-laboratory settings

Infectious disease testing constitutes the largest segment, with respiratory panel testing leading the way, followed by sexually transmitted infections and hospital-acquired infection diagnostics. Oncology molecular POC testing, while smaller, is one of the fastest-growing segments as liquid biopsy technologies mature. Western Europe, Germany, the UK, France, and Italy, dominates market value, though Eastern European markets are growing rapidly as healthcare infrastructure modernizes.

• •Respiratory infectious disease panels represent the largest single testing category
• •Western Europe accounts for the majority of market revenue, with Germany and the UK as key national markets
• •Southern and Eastern European markets expanding as healthcare investment and digital health adoption increase

What are the recent trends and outlook?

Continued growth through 2030 is expected as the market matures beyond pandemic-related demand toward routine clinical use. Integration with telehealth platforms, home testing applications, and artificial intelligence-driven result interpretation are emerging as differentiators. European regulatory alignment under IVDR is simultaneously raising quality standards and creating barriers that favor well-capitalized manufacturers with robust clinical evidence portfolios.

• •Multiplex syndromic panels capable of detecting 10+ pathogens simultaneously becoming the clinical standard
• •Home and community-based testing models expanding as reimbursement pathways develop
• •IVDR regulation tightening compliance requirements while also building clinician and payer confidence